AN2 Therapeutics, Inc. (NASDAQ:ANTX) announced that its board of directors approved a repricing of all outstanding stock options granted under its equity incentive plans prior to March 19, 2026. The ...

Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 Advancing Phase 2 investigator-initiated trial ...

MENLO PARK, Calif. - AN2 Therapeutics Inc. (NASDAQ:ANTX) entered into a securities purchase agreement for a private placement expected to generate gross proceeds of approximately $40 million before ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has ...

MENLO PARK, Calif., March 09, 2026--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its ...

AN2 Therapeutics is currently proceeding through the regulatory clearance process and anticipates initiating the Phase 2 trial in the third quarter of 2026. The company expects to provide data updates ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to ...

MENLO PARK, Calif., March 03, 2026--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its ...

Investors might want to bet on AN2 Therapeutics, Inc. (ANTX), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

The Honda Fit just received a striking facelift in China, featuring sharp new styling. Sadly, this updated hatchback won’t make it to U.S. showrooms. The Honda Fit has been updated in China with a ...